Drug Trial Radar · NCT05364944
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
19
Actual
Start
May 18, 2022
Primary completion
Oct 29, 2024
Study completion Dec 3, 2024
Sponsor
- Lead sponsor
- Debiopharm International SAIndustry
- Sponsor type
- Industry
- First posted
- May 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine tumors (GEP-NETs).
Conditions
- Acromegaly
- GEP-NET
Interventions
Debio 4126Drug
Intramuscular (IM) injection
Sandostatin LARDrug
Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration
Somatuline ATGDrug
Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Concentration of Debio 4126 in Acromegaly and GEP-NET ParticipantsTime frame: Predose at Days -28 to -7; Postdose at multiple timepoints from Day 1 to Day 337
Locations
14 sites in 8 countries. Site status is shown where the registry gives one.
Rigshospitalet, Endokrinologisk afdeling
Copenhagen, Denmark
CHU Angers
Angers, France
AP-HP Hopital Bicetre
Le Kremlin-Bicêtre, France
AP-HM - Hôpital de la Conception, Service d'Endocrinologie et Centre de Référence des Maladies Rares de l'hypophyse
Marseille, France
Medicover Praxis fur Neuroendokrinologie
Munich, Germany
Rabin Medical Center, Beilinson Hospital, Clalit Health Services by Rabin Medical Center, Beilinson Hospita
Petah Tikva, Israel
Sheba Medical Center, Endocrine institute
Ramat Gan, Israel
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milan, Italy
Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowicach
Katowice, Poland
Mazowiecki Szpital Brodnowski - Zespol Oddzialow Chorob Wewnetrznych, Endokrynologii i Diabetologii
Warsaw, Poland
Hospital de la Santa Creu i Sant Pau Barcelon
Barcelona, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
University Hospital Coventry, WISDEM Centre, UHCW NHS Trust
Coventry, United Kingdom
Royal Free London NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.